Mersana Therapeutics logo
Mersana Therapeutics MRSN
$ 1.61 -7.76%

Quarterly report 2024-Q3
added 11-13-2024

report update icon

Mersana Therapeutics Financial Statements 2011-2024 | MRSN

Annual Financial Statements Mersana Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

575 M 567 M 310 M 1.12 B 304 M 105 M 181 M - - - - - -

Shares

116 M 93.7 M 70.6 M 61.5 M 43.5 M 23 M 12 M - - - - - -

Historical Prices

4.95 6.05 4.39 18.2 8.66 5.51 17.3 - - - - - -

Net Income

-172 M -204 M -170 M -88 M -28.2 M -64.3 M -38.7 M -13.7 M -16.4 M - - - -

Revenue

36.9 M 26.6 M 43 K 828 K 42.1 M 10.6 M 17.5 M 25.2 M 10.4 M - - - -

Cost of Revenue

- - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - -

Operating Income

- - - - - - - - - - - - -

Interest Expense

4.07 M 3.33 M 1.27 M 359 K 234 K - - - -89 K - - - -

EBITDA

1.52 M 927 K 855 K 1.01 M -29 M -64.4 M -38.7 M -13.2 M -16 M - - - -

Operating Expenses

217 M 230 M 169 M 88.9 M 72.3 M 76.2 M 57.2 M - - - - - -

General and Administrative Expenses

59.5 M 57 M 36.9 M 21.9 M 17.3 M 16.3 M 10.5 M 6.98 M 5.35 M - - - -

All numbers in USD currency

Quarterly Income Statement Mersana Therapeutics

2024-Q3 2024-Q2 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

123 M 122 M 121 M 121 M 116 M 108 M 105 M 97.6 M 95.8 M 79.9 M 73.7 M 71.8 M 69.6 M 69 M 68.6 M 68.4 M 60.7 M 48 M 47.9 M 47.8 M 47.7 M 30.3 M 23.2 M 23.2 M 23 M 22.8 M 22.8 M 22.2 M 1.41 M 1.34 M 1.29 M 1.28 M 1.25 M 1.24 M - - - - - - - - - - - - - - - - - - - -

Net Income

-11.5 M -24.3 M - -41.7 M -54.3 M -56.2 M - -59.8 M -52.2 M -47.3 M - -45.5 M -40.9 M -34.7 M -28.8 M -22.5 M -28.8 M -28.8 M -16.2 M -16.2 M -16.2 M -16.2 M -22.4 M -22.4 M -22.4 M -22.4 M -14 M -38.7 M -38.7 M -38.7 M 1.26 M -13.7 M -13.7 M -5.36 M - - - - - - - - - - - - - - - - - - - -

Revenue

12.6 M 2.29 M - 7.7 M 10.7 M 7.8 M - 5.57 M 4.28 M 2.04 M - 11 K 11 K 11 K 10 K 11 K 796 K 11 K 42 K 844 K 202 K 41 M 1.19 M 2.15 M 4.19 M 3.06 M 3.26 M 6.27 M 3.73 M 4.29 M 12 M 3.26 M 6.22 M 3.7 M - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - 1.02 M 1.02 M 983 K - 880 K 760 K 724 K - 98 K 95 K 93 K 92 K 92 K 87 K 88 K 87 K 107 K 40 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - 319 K - 645 K 432 K 205 K - 644 K 432 K 226 K - 750 K 494 K 248 K - 963 K 653 K 337 K - 907 K 565 K 258 K - 673 K 438 K 209 K - 449 K 265 K - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

24.7 M 27.7 M - 51.6 M 67.2 M 65.6 M - 65.2 M 56 M 48.6 M - 45.4 M 40.8 M 34.6 M 28.8 M 22.4 M 20.6 M 17.2 M 16.6 M 18.1 M 18 M 19.6 M 24 M 19.6 M 16.9 M 15.8 M 17.6 M 14.3 M 12.8 M 12.4 M 10.8 M 9.15 M 10 M 9.06 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

9.86 M 10.5 M - 12.9 M 18.2 M 18.3 M - 14.6 M 14.8 M 12.8 M - 10.1 M 8.88 M 7.21 M 5.91 M 5.88 M 5.17 M 4.94 M 4.21 M 4.44 M 4.19 M 4.44 M 4.15 M 4.38 M 4.23 M 3.57 M 3.06 M 2.9 M 2.2 M 2.3 M 1.94 M 1.6 M 1.83 M 1.62 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency